BIOMERICA INC (BMRA) Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste. Biomerica primarily sells its products for gastrointestinal disorders, food sensitivities, diabetes, and a variety of specialized diagnostic evaluations. Its distribution channels include physicians' clinics, retail pharmacies, and hospital/clinical laboratories. The company is currently developing InFoods, a diagnostic-guided therapy technology for irritable bowel syndrome; products for Helicobacter pylori; and comprehensive diagnostic tools for COVID-19, encompassing their development, testing, validation, and sale. Established in 1971, Biomerica, Inc. maintains its corporate headquarters in Irvine, California.
Sector: In Vitro & In Vivo Diagnostic Substances
Industry: Medical - Devices
Biomerica, Inc. NASDAQ:BMRA Healthcare · Medical - Devices
Mkt Cap $7.91M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release ⚠ 4
Biomerica Reports First Quarter Fiscal 2027 Financial Results
Biomerica reported Q1 fiscal 2027 net sales of approximately $1.3 million, down from $1.4 million a year ago, with a net loss of $1.2 million ($0.37 per share) versus prior-year breakeven that included ~$1.1 million of ERC income.
Commercial momentum is building for inFoods IBS: Medicare-related test orders rose 120% month-over-month to 22 in September, and 100% of initial valid Medicare claims have been paid at the full $300 CMS rate.
Cash more than doubled to $2.7 million following an August private placement at $1.60 per share that raised $2.23 million, with participation from B. Riley Principal Capital and all board members.
The company engaged B. Riley Securities as exclusive financial advisor to evaluate strategic opportunities including partnerships and business combinations — a potential M&A signal for this micro-cap diagnostics firm.
• 16d ago AI analysis › Press Release ⚠ 2
Biomerica Reports Fiscal 2026 Year-End Financial Results
Biomerica reported fiscal 2026 revenue of $4.50 million, down from $5.30 million in the prior year, while its net loss narrowed 24% to $3.8 million or $(1.30) per share.
Operationally, the company confirmed that 100% of valid Medicare claims for its InFoods IBS test have been paid at the full $300 rate, and it secured a $1.75 million CDMO agreement to develop proprietary IVD assays.
Subsequent to year-end, Biomerica closed a $2.23 million private placement at $1.60 per share and engaged B. Riley Securities to explore strategic alternatives including partnerships and business combinations.
• 2mo ago AI analysis › Press Release ● Critical
Biomerica Announces $2.23 Million Financing
Biomerica secured $2.23 million in gross proceeds through a private placement of 1.39 million shares priced at $1.60 per share, with no warrants or discounted securities included.
The financing represents approximately 30.4% dilution on a pro forma basis but was fully subscribed by the company's CEO, all Board members, and B. Riley Principal Capital, demonstrating strong insider alignment.
Concurrent with the capital raise, Biomerica engaged B. Riley as its exclusive financial advisor to evaluate strategic alternatives, including potential acquisitions, mergers, and partnerships.
• 2mo ago AI analysis › Press Release ⚠ 3
Biomerica Lands a $1.75 Million CDMO Master Services Agreement for IVD Diagnostic Development
Biomerica signed a Master Services Agreement with a confidential life sciences partner to develop proprietary IVD assays.
The deal carries an initial target fee of $1.75 million, to be earned over a three-year term with automatic renewals.
Management highlights that this leverages existing infrastructure and scientific capabilities, creating a capital-efficient revenue stream alongside its primary inFoods® IBS product.
• 5mo ago AI analysis › Press Release
Biomerica’s inFoods® IBS Data Accepted for Presentation at Digestive Disease Week 2026
Biomerica announced that an abstract evaluating the real-world clinical effectiveness of its inFoods® IBS diagnostic-guided therapy has been accepted for poster presentation at Digestive Disease Week 2026 in Chicago.
The study, conducted by investigators from Michigan Medicine and Cleveland Clinic, builds on previously published trial data showing 59.6% of the treatment group achieved the FDA endpoint for abdominal pain reduction versus 42.1% in the control group.
The company estimates the total addressable market for IBS treatments at $30 billion, affecting 30 to 45 million adults in the United States.
• 6mo ago AI analysis › Press Release
Biomerica Announces Medicare Administrative Contractor Confirmation of Individual Claim Review for inFoods® IBS, Opening a Scalable Medicare Commercialization Pathway
globenewswire.com • 6mo ago Press Release
Biomerica Launches inFoods® IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs
globenewswire.com • 6mo ago Press Release ● Major
Biomerica Reports Third Quarter Fiscal 2026 Financial Results
globenewswire.com • 6mo ago 
